HPCM
WST icon

High Pointe Capital Management’s West Pharmaceutical WST Stock Holding History

High Pointe Capital Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,120
Closed -$385K – 95
2018
Q3 		$385K Hold
3,120
– – 0.52% 62
2018
Q2 		$310K Hold
3,120
– – 0.44% 69
2018
Q1 		$275K Hold
3,120
– – 0.38% 75
2017
Q4 		$308K Buy
+3,120
New +$306K 0.42% 70

Other funds holding WST

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

High Pointe Capital Management's WST Position: Q4 2018 in Review

High Pointe Capital Management sold out of West Pharmaceutical (WST) in Q4 2018, closing a stake of 3,120 shares — an estimated $385K sold.

High Pointe Capital Management first reported a position in WST in Q4 2017 and held it in 4 quarters. The position peaked at $385K in Q3 2018. 355 funds tracked by Wall St. Rank hold WST as of Q4 2018.

  • High Pointe Capital Management reported no remaining West Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • High Pointe Capital Management sold 3,120 West Pharmaceutical shares in Q4 2018, an estimated $385K.
  • High Pointe Capital Management first reported a position in West Pharmaceutical in Q4 2017 and held it in 4 quarters.
  • High Pointe Capital Management's West Pharmaceutical position peaked at $385K in Q3 2018.
  • 355 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2018.

Based on High Pointe Capital Management's 13F filing for Q4 2018, filed 4 Feb 2019.